Oxycodone hydrochloride hydrate controlled-release - Daiichi Sankyo

Drug Profile

Oxycodone hydrochloride hydrate controlled-release - Daiichi Sankyo

Alternative Names: DS-5058b; Oxycodone hydrochloride trihydrate

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 30 Nov 2017 Daiichi Sankyo plans a phase I bioequivalence trial in healthy volunteers in Japan (JapicCTI-173793)
  • 07 Jun 2017 Daiichi Sankyo plans a phase I trial in Healthy volunteers in Japan (JapicCTI-173606)
  • 10 Mar 2017 No development reported - Phase-I for Pain (In volunteers) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top